The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 798 studies for Carcinoma, Ovarian Epithelial across more than 10 countries. 102 are recruiting or about to start. 365 of them are mainly about Carcinoma, Ovarian Epithelial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.
ClinicalTrials.gov finds 1,684 studies for Carcinoma, Ovarian Epithelial.How that becomes 796 hereChecked on ClinicalTrials.gov . The studies here are updated every night.
This page counts the studies the registry files under Carcinoma, Ovarian Epithelial, and those it files under no condition that list Carcinoma, Ovarian Epithelialthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count
1,684Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−23List Carcinoma, Ovarian Epithelial as a condition, but the registry did not file them under itMost often written as “Ovarian Epithelial Cancer Recurrent” (6), “Advanced Epithelial Ovarian Cancer” (3), and “Platinum-Resistant Epithelial Ovarian Cancer” (2). The registry filed them under other conditions only, most often Ovarian Neoplasms (14) and Fallopian Tube Neoplasms (8).
−865Match it another way203 name it in the title, 8 in a keyword, and 654 by a synonym or other text the search reads.
796The count on this page11 of them list Carcinoma, Ovarian Epithelial in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 20 programs from 15 companies, 15 with this as their studies’ main aim; 9 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Beijing Biotech, Bracco and Sichuan Biokin Pharmaceutical here →
Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 5 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (4)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
17 Feb 2027 est.Dual-target CAR-NK cell product, Lymphodepleting chemotherapy· Beijing Biotech · Phase 2main aimNCT07480954 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) — primary endpoint: Incidence of dose-limiting toxicities (DLTs) · 36 enrolled
14 Mar 2027 est.EB-DUALNK· Beijing Biotech · Phase 2main aimstudied with Cyclophosphamidestudied with fludarabineNCT07589543 Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer — primary endpoint: Incidence of dose-limiting toxicities (DLTs) to determine maximum tolerated dose (MTD) · 42 enrolled
Jun 2027 est.izalontamab brengitecan· Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3main aimNCT06994195 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) — primary endpoint: Progression-free survival (PFS) · 450 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Carcinoma, Ovarian Epithelial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
34studies finish main data collection within a year4 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger. 2 (3%) take children under 18. 58 (77%) are for women only and 0 (0%) for men only; 4 (5%) take healthy volunteers.
Across all 798 studies, recruiting or not: 11% stop at 75 or younger and 3% at 65; 13% take children; 72% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Carcinoma, Ovarian Epithelial studies take
Of 55 phase 1 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 44 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
44 mo34–81 · 55 studies
—
39 mo32–54 · 29 studies
Phase 1/2
60 mo37–74 · 26 studies
—
—
Phase 2
72 mo45–92 · 51 studies
—
—
Phase 3
55 mo38–110 · 33 studies
—
—
Interventional, no phase
66 mo43–93 · 30 studies
—
—
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 19, 2026.